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Poster Session II S311preliminary results from an IRB-approved prospective, open label,
phase II trial to test the efficacy of montelukast, a leukotriene in-
hibitor, for the treatment of BOS after HSCT. BOS diagnostic
criteria included: FEV1\75%, FEV1/VC\0.7 or air trapping
on CT and RV. 120% or RV/TLC. 120% in the absence of in-
fection and presence of another cGVHD manifestation. Eleven
patients have enrolled to date. One withdrew prior to medication
initiation and 9/10 are currently on study medication (10 mg mon-
telukast po nightly). Patient characteristics include age range
15-60 years, 7/11 female, baseline FEV1 range from 33 to 71%
predicted, and 3/11 patients requiring oxygen supplementation.
Sixty-four % (7/11) have reached the primary endpoint (6 months
of study drug). FEV1 increased by 6-10% predicted in 3 patients,
remained stable in 3, and declined by less than 15% in 1. Slope of
the FEV1 value generated as linear regression of FEV1 volume vs.
days post-transplant revealed: 5/7 increase in slope, 2/7 decrease
in slope from pre-study FEV1 values. Three patients had immu-
nosuppression reduced during this time period with complete ces-
sation of tacrolimus in 1, cessation of steroids in 1, and decreased
tacrolimus in 1(including 2 with stable FEV1 and 1 with increase
in FEV1); 1 patient had an increase in steroid dose less than 1 mg/
kg/day. Two patients had worsening of other cGVHD manifesta-
tions on study, including a skin flare that resolved without increas-
ing systemic therapy (1) and gastrointestinal cGVHD flare that
improved with increased steroids including local therapy (1). Mon-
telukast was well-tolerated with one grade II attributable adverse
event (insomnia) during the six-month collection period.
Improvements were also noted in oral mucosa cGVHD manifesta-
tions in 3/7 and liver in 2/7. These preliminary findings suggest
that montelukast may have a role in the therapy of BOS after
allogeneic HSCT.417
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Background: Thalidomide is active in cGVHD, but with trouble-
some side effects such as neutropenia, neuropathy and somnolence.
POM is a member of the new class of immune-modulating drugs
(IMiD) .100-fold more potent than thalidomide in inhibiting
production of TNFa and increasing Th1-cells. We assessed effi-
cacy and safety of POM in people with corticosteroid-resistant
cGVHD.
Methods: Subjects had to have moderate (N5 2) or severe
(N5 6) cGVHD (NIH criteria), and failed prednisone (0.5 mg/
kg/d for .8 w) and/or 2nd-line immune-suppression. No ECP
in the preceding 3 m or new therapy in the preceding 1 m was al-
lowed. POM was given by mouth at a starting dose of 3 mg/d with
dose-reduction to 2, 1, and 0.5 mg/d for intolerance or adverse
events. Subjects were evaluated for response every 3 m. Responses
were assessed based upon changes in signs or symptoms of each
organ system and overall response was than determined using
NIH Criteria.
Results: 8 subjects are enrolled so far. Median time posttransplant is
2.9 y (1.5-6 y), median time since diagnosis of cGVHD is 1.8 y (1-4.5
y), 4 subjects received related- and 4 unrelated-allotransplants; 5 had
prior acute GVHD. Median N of prior systemic cGVHD therapies
was 3 (2-5). Affected organs included skin (N5 8), mouth (N5 8),
eye (N5 7), GI (N5 5), musculo-skeletal (N5 4), liver (N5 2),
genital (N5 2) and lung (N5 2). Median KPS was 80%. 7 subjects
required dose-reductions for muscle cramps, tremors and/or fatigue.
There was no bonemarrow suppression, neuropathy, somnolence or
thrombosis. 5 subjects discontinued therapy: 1 for worsening skin
andmouth lesions, 3 for no response (2 had worsening tremors, mus-
cle cramps and fatigue) and 1 for worsening pain. 1 subject died of
a heart attack 4 m after stopping POM. 3 subjects completed 6 m
of therapy and underwent 2nd response evaluation: 2 at 2 mg/d
and 1 at 1 mg/d. 2 have a complete response (CR) and 1 a partial re-
sponse (PR) of erythematous skin changes and aCR ofGI symptoms.There are ongoing improvements\PR in skin, mouth, and eyes. 3
subjects have a global PR.
Conclusion: POM can be given for corticosteroid-resistant
cGVHD without toxicities that limit use of thalidomide in this
context. Our data suggest POM is active in moderate/severe corti-
costeroid-resistant cGVHD. 3 mg/d is likely a too high starting
dose: we recommend 1-2 mg/d in future studies. Subject accrual
continues, as do correlative laboratory studies; these data will be
reported.418
A PROSPECTIVE STUDY OF DONOR IMMUKNOW AS A BIOMARKER FOR
ACUTE GVHD IN HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS
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Introduction:Graft versus host disease (GvHD) occurs in40% of
allogeneic hematopoietic cell transplantation (HCT) recipients and
is associated with substantial morbidity and mortality. Immunolog-
ical parameters of donor cells that predispose a recipient to GvHD
will be of great value. The Cylex ImmuKnow assay determines
the strength of immune function by quantifying the amount of
ATP released from phytohemagglutinin-stimulated peripheral
bloodCD4+ cells. In our current study, we utilized the ImmuKnow
to assess whether a donor’s immune response correlates with early
outcomes in recipients post-HCT.
Patients and Methods: Twenty-six (26) donor-recipient pairs were
included in our study (15 HLA identical siblingHCT and 11 haploi-
dentical HCT). Recipients received an average cell-dose of
10.76 4.9  106 CD34+ cells/kg. Blood samples obtained prior to
G-CSFmobilization and prior to stem cell collection (approximately
2 weeks apart) were assayed for ImmuKnow values and cell counts
(WBC, ANC, ALC & CD34+ count).
Results:G-CSF mobilization led to a significant increase in Immu-
Know ATP values from 342 to 728 ng/mL (p\0.001) along with
an increase in all measured cell counts. Grade$ II acute GvHD oc-
curred in 27% of haploidentical HCT recipients (3/11 patients)
and 20% of HLA identical HCT recipients (3/15 patients). In hap-
loidentical HCT, mobilized donor blood ImmuKnow ATP
values did not correlate with GvHD. However, donor Immu-
Know values correlated with increased risk of acute GvHD in
HLA identical sibling HCT. In HLA identical sibling HCT,
ATP values in excess of 747 ng/mL predicted grade II or higher
GvHD with a likelihood ratio of 4.00 (2.9-5.5, 95% confidence),
sensitivity of 100%, and specificity of 75% (AUC5 0.889,
p5 0.003).
Conclusions: If confirmed in larger studies, these data suggest that
ImmuKnow can serve as an independent predictor/biomarker for the
development of GvHD in HLA identical HCT.419
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Chronic graft-versus-Host-Disease (GVHD) is observed in up to
50% of long term survivors of hematopoietic stem cell transplants
(HSCT) and is associated to important morbidity and mortality.
Mycophenolate Mofetil (MMF) has been used as therapy for refrac-
tory chronicGVHDwith good efficacy and tolerability.We describe
our experience at Hospital de clınicas of Federal University of Par-
ana-Brazil during the last ten years on the use of this drug as rescue
for refractory chronic GVHD.
